Pfizer 2008 Annual Report Download - page 23

Download and view the complete annual report

Please find page 23 of the 2008 Pfizer annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 100

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100

Financial Review
Pfizer Inc and Subsidiary Companies
Revenues—Major Pharmaceutical Products
Revenue information for several of our major Pharmaceutical products follows:
(MILLIONS OF DOLLARS)
PRODUCT
YEAR ENDED DECEMBER 31, % CHANGE
PRIMARY INDICATIONS 2008 2007 2006 08/07 07/06
Cardiovascular and
metabolic diseases:
Lipitor Reduction of LDL cholesterol $12,401 $12,675 $12,886 (2) (2)
Norvasc Hypertension 2,244 3,001 4,866 (25) (38)
Chantix/Champix An aid to smoking cessation 846 883 101 (4) 773
Caduet Reduction of LDL cholesterol and
hypertension 589 568 370 454
Cardura Hypertension/Benign prostatic hyperplasia 499 506 538 (1) (6)
Central nervous system
disorders:
Lyrica Epilepsy, post-herpetic neuralgia and
diabetic peripheral neuropathy,
fibromyalgia 2,573 1,829 1,156 41 58
Geodon/Zeldox Schizophrenia and acute manic or mixed
episodes associated with bipolar disorder 1,007 854 758 18 13
Zoloft Depression and certain anxiety disorders 539 531 2,110 2(75)
Aricept(a) Alzheimer’s disease 482 401 358 20 12
Neurontin Epilepsy and post-herpetic neuralgia 387 431 496 (10) (13)
Xanax/Xanax XR Anxiety/Panic disorders 350 325 316 83
Relpax Migraine headaches 321 315 286 210
Arthritis and pain:
Celebrex Arthritis pain and inflammation, acute pain 2,489 2,290 2,039 912
Infectious and respiratory
diseases:
Zyvox Bacterial infections 1,115 944 782 18 21
Vfend Fungal infections 743 632 515 18 23
Zithromax/Zmax Bacterial infections 429 438 638 (2) (31)
Diflucan Fungal infections 373 415 435 (10) (5)
Urology:
Viagra Erectile dysfunction 1,934 1,764 1,657 10 6
Detrol/Detrol LA Overactive bladder 1,214 1,190 1,100 28
Oncology:
Sutent Advanced and/or metastatic renal cell
carcinoma (mRCC) and refractory
gastrointestinal stromal tumors (GIST) 847 581 219 46 166
Camptosar Metastatic colorectal cancer 563 969 903 (42) 7
Aromasin Breast cancer 465 401 320 16 25
Ophthalmology:
Xalatan/Xalacom Glaucoma and ocular hypertension 1,745 1,604 1,453 910
Endocrine disorders:
Genotropin Replacement of human growth hormone 898 843 795 66
All other:
Zyrtec/Zyrtec D Allergies 129 1,541 1,569 (92) (2)
Alliance revenues Alzheimer’s disease (Aricept), neovascular
(wet) Age-related macular degeneration
(Macugen), Parkinson’s disease (Mirapex),
hypertension (Exforge and Olmetec),
multiple sclerosis (Rebif) and chronic
obstructive pulmonary disease (Spiriva) 2,251 1,789 1,374 26 30
(a) Represents direct sales under license agreement with Eisai Co., Ltd.
Certain amounts and percentages may reflect rounding adjustments.
Pharmaceutical—Selected Product Descriptions
•Lipitor, for the treatment of elevated LDL-cholesterol levels in the blood, is the most widely used prescription treatment for lowering
cholesterol and the best-selling pharmaceutical product of any kind in the world. Lipitor recorded worldwide revenues of $12.4 billion in
2008, a decrease of 2% compared to 2007 despite the favorable impact of foreign exchange, which increased revenues by
approximately $310 million, or 2%. In the U.S., revenues of $6.3 billion in 2008 declined 12% compared to 2007. Internationally, Lipitor
revenues in 2008 increased 11% compared to 2007, with 6% due to the favorable impact of foreign exchange.
2008 Financial Report 21